Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Ionis Pharmaceuticals, Inc. (IONS : NSDQ)
 
 • Company Description   
Ionis Pharmaceuticals discovers/develops RNA-targeted therapeutics using its proprietary antisense oligonucleotide technology. Its antisense medicines have been developed/are being developed to treat neurological, cardiovascular and specialty rare diseases.

Number of Employees: 1,069

 
 • Price / Volume Information   
Yesterday's Closing Price: $73.55 Daily Weekly Monthly
20 Day Moving Average: 2,083,092 shares
Shares Outstanding: 161.97 (millions)
Market Capitalization: $11,913.22 (millions)
Beta: 0.33
52 Week High: $76.78
52 Week Low: $23.95
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 5.12% 2.36%
12 Week 68.00% 61.03%
Year To Date 110.38% 83.90%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2855 GAZELLE COURT
-
CARLSBAD,CA 92010
USA		 ph: 760-931-9200
fax: 760-603-2700		 ir@ionis.com https://ionis.com
 
 • General Corporate Information   
Officers
Brett P. Monia - Chief Executive Officer;Director
Joseph Loscalzo - Chairman of the Board
Elizabeth L. Hougen - Executive Vice President; Finance and Chief Financ
Spencer R. Berthelsen - Director
Allene M. Diaz - Director

Peer Information
Ionis Pharmaceuticals, Inc. (GSAC)
Ionis Pharmaceuticals, Inc. (CASI)
Ionis Pharmaceuticals, Inc. (ALCD.)
Ionis Pharmaceuticals, Inc. (OMNN)
Ionis Pharmaceuticals, Inc. (CGPI.)
Ionis Pharmaceuticals, Inc. (CATX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 462222100
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 02/18/26
Share - Related Items
Shares Outstanding: 161.97
Most Recent Split Date: (:1)
Beta: 0.33
Market Capitalization: $11,913.22 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.34 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.38 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 12.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 02/18/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 19.28
Price/Cash Flow: -
Price / Sales: 12.31
EPS Growth
vs. Year Ago Period: 15.79%
vs. Previous Quarter: -214.29%
Sales Growth
vs. Year Ago Period: 17.16%
vs. Previous Quarter: -65.27%
ROE
09/30/25 - -44.26
06/30/25 - -45.29
03/31/25 - -91.85
ROA
09/30/25 - -8.65
06/30/25 - -8.99
03/31/25 - -15.77
Current Ratio
09/30/25 - 2.79
06/30/25 - 2.87
03/31/25 - 9.66
Quick Ratio
09/30/25 - 2.78
06/30/25 - 2.86
03/31/25 - 9.62
Operating Margin
09/30/25 - -26.45
06/30/25 - -28.25
03/31/25 - -63.65
Net Margin
09/30/25 - -26.45
06/30/25 - -28.25
03/31/25 - -63.65
Pre-Tax Margin
09/30/25 - -26.73
06/30/25 - -29.04
03/31/25 - -64.65
Book Value
09/30/25 - 3.82
06/30/25 - 3.96
03/31/25 - 2.99
Inventory Turnover
09/30/25 - 1.10
06/30/25 - 0.69
03/31/25 - 0.52
Debt-to-Equity
09/30/25 - 0.96
06/30/25 - 0.99
03/31/25 - 2.63
Debt-to-Capital
09/30/25 - 49.09
06/30/25 - 49.75
03/31/25 - 72.44
 

Powered by Zacks Investment Research ©